EMA/439207/2019

European Medicines Agency decision

P/0327/2019

of 11 September 2019

on the acceptance of a modification of an agreed paediatric investigation plan for etrolizumab (EMEA-001434-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0327/2019

of 11 September 2019

on the acceptance of a modification of an agreed paediatric investigation plan for etrolizumab (EMEA-001434-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0022/2014 issued on 22 January 2014 and the decision P/0148/2015 issued on 10 July 2015,

Having regard to the application submitted by Roche Registration GmbH on 16 April 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for etrolizumab, solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 - Grenzach-Wyhlen, Germany.

EMA/PDCO/261002/2019
Amsterdam, 26 July 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001434-PIP01-13-M02

Scope of the application

Active substance(s):

Etrolizumab

Condition(s):

Treatment of ulcerative colitis

Treatment of Crohn's disease

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Roche Registration GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Roche Registration GmbH submitted to the European Medicines Agency on 16 April 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0022/2014 issued on 22 January 2014 and the decision P/0148/2015 issued on 10 July 2015.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 28 May 2019.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of ulcerative colitis

The waiver applies to:

- the paediatric population from birth to less than 4 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

1.2. Condition:

Treatment of Crohn's disease

The waiver applies to:

- the paediatric population from birth to less than 4 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Treatment of ulcerative colitis

2.1.1. Indication(s) targeted by the PIP

Treatment of moderately to severely active ulcerative colitis in children and adolescents who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine or azathioprine and/or anti-TNF agents, or who are intolerant to or have medical contraindications for such therapies

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of solution for injection in vial 50 mg/ml and solution for injection in pre-filled syringe 50 mg/ml
Non-clinical studies	1	**Study 2** Evaluation of potential effects of etrolizumab on pregnant / lactating female mice and on development of the foetus and offspring following exposure of the female mice from implantation through weaning
Clinical studies	2	**Study 3** Phase 1, open-label, randomised, pharmacokinetic, pharmacodynamic and safety study of etrolizumab, followed by an open-label extension and safety monitoring in paediatric patients from 4 to less than 18 years of age with moderate to severe ulcerative colitis or moderate to severe Crohn's disease **Study 4** Double-blind, randomised, multi-centre, multiple-dose, placebo controlled trial to evaluate efficacy of etrolizumab in inducing and maintaining clinical remission in children from 4 years to less than 18 years of age with moderate to severe active ulcerative colitis and to evaluate etrolizumab safety and tolerability during induction and maintenance therapy
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.2. Condition:

Treatment of Crohn's disease

2.2.1. Indication(s) targeted by the PIP

Treatment of moderately to severely active Crohn's disease in children and adolescents who have had an inadequate response, loss of response, or intolerance to immunosuppressants, corticosteroids, or TNF blockers

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Solution for injection

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** The same study as for the condition Treatment of ulcerative colitis
Non-clinical studies	1	**Study 2** The same study as for the condition Treatment of ulcerative colitis
Clinical studies	2	**Study 3** The same study as for the condition Treatment of ulcerative colitis **Study 5** Double-blind, randomised, multi-centre, placebo controlled trial to evaluate efficacy of etrolizumab in inducing and maintaining clinical remission in children from 4 years to less than 18 years of age with moderate to severe active Crohn's disease and to evaluate etrolizumab safety and tolerability during induction and maintenance therapy
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes